Analytical Data
-
Gene name
HLA-B*15:02&B2M Monomer
- Application
-
Alternative Names
HLA-B*1502 & B2M
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59630.1 (G25-V309)&P61769
-
Expression Region
AAA59630.1 (G25-V309)&P61769 (I21-M119)
-
Molecular Weight
40-43 kDa and 8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-B*15:02 is a critical human leukocyte antigen associated with drug hypersensitivity reactions, particularly severe adverse reactions to carbamazepine, an anticonvulsant medication. The presence of this specific allele in individuals of Asian descent has been linked to an increased risk of developing Stevens-Johnson syndrome and toxic epidermal necrolysis, making its study essential for personalized medicine and pharmacogenomics. B2M, or beta-2-microglobulin, is a component of the major histocompatibility complex (MHC) class I molecules and plays a pivotal role in the immune response by stabilizing these complexes on the cell surface. Research involving the recombinant proteins of HLA-B*15:02 and B2M aims to elucidate the molecular mechanisms underlying drug hypersensitivity, improve diagnostic strategies, and develop potential therapeutic interventions. By examining the interaction between HLA-B*15:02 and B2M at a molecular level, scientists can gain insights into how specific genetic backgrounds can predispose individuals to severe drug reactions. This research is vital for enhancing drug safety, facilitating tailored treatment plans based on genetic profiling, and ultimately improving patient outcomes in populations at risk for adverse drug reactions.
